---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-030888"
form_type: "8-K"
ticker: "GILD"
cik: "0000882095"
company_name: "GILEAD SCIENCES, INC."
filed_at: "2022-03-07T23:59:59+00:00"
generated_at: "2026-06-27T01:22:32.554833+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Gilead's Trodelvy meets Phase 3 endpoint in HR+/HER2- metastatic breast cancer

## Summary
- TROPiCS-02 met primary endpoint: statistically significant PFS improvement vs physician's choice chemo in 543 patients.
- First interim OS analysis showed numerical improvement but not statistically significant; final OS readout expected in 2024.
- Safety profile consistent with prior studies; no new safety concerns observed.
- Gilead reaffirms 2022 guidance; oncology revenue goal of 1/3 by 2030 unchanged.

## SEC filing metadata
- accession: 0001104659-22-030888
- form_type: 8-K
- ticker: GILD
- cik: 0000882095
- company_name: GILEAD SCIENCES, INC.
- filed_at: 2022-03-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882095/000110465922030888/0001104659-22-030888-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882095/000110465922030888/tm228518d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-030888
- JSON: https://secwatch.observer/filing/0001104659-22-030888.json
- Plain text: https://secwatch.observer/filing/0001104659-22-030888.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.